Abstract

The first contains specific recommendations for screening and surveillance in people at average and at high risk for colorectal cancer. The second section describes the evidence used to develop the recommendations. Screening, diagnostic evaluation, and surveillance strategies are presented as options that the panel thought were acceptable, based on the evidence. The options differ in strength of evidence, size of benefit, clinical performance, and effectiveness in preventing colorectal cancer, simplicity, safety, patient acceptance, cost, and cost-effectiveness.